This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Kazia Therapeutics 미래 성장

Future 기준 확인 3/6

Kazia Therapeutics (는) 각각 연간 49.6% 및 47.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 59.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 25% 로 예상됩니다.

주요 정보

49.6%

수익 성장률

59.7%

EPS 성장률

Biotechs 수익 성장	14.9%
매출 성장률	47.7%
향후 자기자본 수익률	25.0%
애널리스트 커버리지	Low
마지막 업데이트	10 Aug 2023

최근 미래 성장 업데이트

Recent updates

We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

Jun 24

We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

Feb 24

We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned

Nov 03

We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth

Sep 23

We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth

May 04

When Will Kazia Therapeutics Limited (ASX:KZA) Turn A Profit?

Mar 27

Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?

Feb 28

What Can We Learn About Kazia Therapeutics' (ASX:KZA) CEO Compensation?

Feb 01

We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth

Jan 06

Bullish: Analysts Just Made An Incredible Upgrade To Their Kazia Therapeutics Limited (ASX:KZA) Forecasts

Dec 11

Kazia Therapeutics Limited (ASX:KZA): When Will It Breakeven?

Nov 26

수익 및 매출 성장 예측

ASX:KZA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (AUD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2026	3	-17	N/A	N/A	1
6/30/2025	11	-6	7	7	2
6/30/2024	11	-7	7	7	2
6/30/2023	0	-20	-15	-15	N/A
3/31/2023	0	-23	-18	-18	N/A
12/31/2022	N/A	-25	-20	-20	N/A
9/30/2022	0	-25	-21	-21	N/A
6/30/2022	0	-25	-23	-23	N/A
3/31/2022	8	-20	-15	-15	N/A
12/31/2021	15	-15	-8	-8	N/A
9/30/2021	15	-12	-9	-9	N/A
6/30/2021	15	-8	-9	-9	N/A
3/31/2021	8	-11	-14	-14	N/A
12/31/2020	0	-13	-18	-18	N/A
9/30/2020	1	-13	-14	-14	N/A
6/30/2020	1	-12	-9	-9	N/A
3/31/2020	1	-11	-7	-7	N/A
12/31/2019	1	-10	-5	-5	N/A
9/30/2019	1	-10	-6	-6	N/A
6/30/2019	1	-10	-7	-7	N/A
3/31/2019	2	-11	-6	-6	N/A
12/31/2018	2	-12	-5	-5	N/A
9/30/2018	3	-9	-7	-7	N/A
6/30/2018	3	-6	-9	-9	N/A
3/31/2018	4	-6	-10	-10	N/A
12/31/2017	6	-6	-12	-12	N/A
9/30/2017	7	-8	-12	-12	N/A
6/30/2017	9	-11	-11	-11	N/A
3/31/2017	7	-12	N/A	-12	N/A
12/31/2016	5	-12	N/A	-12	N/A
9/30/2016	4	-12	N/A	-12	N/A
6/30/2016	3	-12	N/A	-12	N/A
3/31/2016	3	-10	N/A	-12	N/A
12/31/2015	3	-9	N/A	-12	N/A
9/30/2015	2	-8	N/A	-9	N/A
6/30/2015	2	-7	N/A	-6	N/A
3/31/2015	2	-7	N/A	-5	N/A
12/31/2014	2	-7	N/A	-5	N/A
9/30/2014	1	-7	N/A	-5	N/A
6/30/2014	0	-7	N/A	-6	N/A
3/31/2014	0	-6	N/A	-5	N/A
12/31/2013	1	-5	N/A	-3	N/A
9/30/2013	1	-3	N/A	-6	N/A
6/30/2013	1	-2	N/A	-9	N/A
3/31/2013	1	-1	N/A	-11	N/A
12/31/2012	1	1	N/A	-13	N/A

애널리스트 미래 성장 예측

수입 대 저축률: KZA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: KZA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: KZA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: KZA 의 수익(연간 47.7% ) Australian 시장( 5.4% 보다 빠르게 성장할 것으로 예상됩니다. 5.4% 연간).

고성장 수익: KZA 의 수익(연간 47.7% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: KZA 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 25 %)

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2023/11/15 14:11
장 마감 주가	2023/11/13 00:00
수익	2023/06/30
연간 수익	2023/06/30

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Kazia Therapeutics Limited 2 애널리스트 중 2 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Soo Romanoff	Edison Investment Research
Nazibur Rahman	Maxim Group

This company listing is no longer active

Kazia Therapeutics 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Forecast to breakeven in 2024

Price target decreased to AU$0.45

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Consensus forecasts updated

Recent updates

Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients

Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP

Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Kazia Therapeutics Limited Announces Appointment of Board Members

Kazia Therapeutics Limited Announces Executive Changes

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $1.981756 million.

Kazia Therapeutics Announces Receipt of Nasdaq Minimum Bid Notification

Kazia Therapeutics Provides Preliminary Update from Ongoing Phase 2 Study of Paxalisib in Primary Cns Lymphoma

New major risk - Market cap size

Kazia Therapeutics Limited Announces Clinical Data At ESMO 2023 from Ongoing Phase 1 ESMO Study

Kazia Therapeutics Limited Announces Acceptance of Late-Breaking Abstracts and Oral Presentation of Pnoc022 Clinical Data At 2023 Society for Neuro-Oncology Annual Meeting

Kazia Therapeutics Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Appoints John Friend as Managing Director

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.5 million.

Kazia Therapeutics Limited Receives Fast Track Designation from FDA for Treatment of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations in Combination with Radiation Therapy

High number of new and inexperienced directors

Kazia Therapeutics Limited Announces Phase II Clinical Study to Investigate Paxalisib in Recurrent/Progressive IDH-Mutant Grade 2 & 3 Glioma

Kazia Therapeutics Limited Appoints Ms. Ebru Davidson to its Board

Forecast to breakeven in 2024

Kazia Announces Receipt of Nasdaq Minimum Bid Notification

Kazia Therapeutics Announces the Publication of Pre-Clinical Data for Its Second Pipeline Asset, EVT801 in the Journal Cancer Research Communications

Kazia Therapeutics Limited Announces Publication of Positive Preclinical Data for Evt801

Price target decreased to AU$0.45

No longer forecast to breakeven

Kazia Therapeutics Limited's Paxalisib Demonstrates Positive Monotherapy Efficacy Signals in Preclinical Models of Melanoma

Kazia Therapeutics Limited Announces Expansion of PNOC Study into Australia

Kazia Therapeutics Limited, Annual General Meeting, Nov 16, 2022

No longer forecast to breakeven

Kazia Therapeutics Limited Presents Promising New Data from an Ongoing Phase I Clinical Trial of Paxalisib in Combination with Radiotherapy

No longer forecast to breakeven

Kazia Therapeutics Limited Provides Progress Update on GBM Agile Pivotal Study

Consensus forecasts updated

Kazia Therapeutics Limited Launches New Scientific Advisory Board

Kazia Therapeutics Limited Launches New Scientific Advisory Board

United States Food and Drug Administration Awards Rare Pediatric Disease Designation to Kazia Therapeutics Limited's Paxalisib for AT/RT, Rare Form of Childhood Brain Cancer

Kazia Therapeutics Limited Provides Progress Update on Paxalisib and EVT801 Clinical Programs

We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

Consensus forecasts updated

Kazia Therapeutics Limited Announces Phase II Study of Paxalisib in Brain Metastases Advances to Expansion Stage in Breast Cancer Brain Metastases Cohort

Kazia Presents Positive Final Data from Phase II Study of Paxalisib in Newly Diagnosed Glioblastoma at ASCO Conference

Kazia to Present Final Data from Paxalisib Phase II Study in Glioblastoma At ASCO

Insufficient new directors

Kazia Therapeutics Limited Announces Phase II Study of Paxalisib in Glioblastoma Achieves Final Completion

Kazia Presents Preclinical Data for Paxalisib At AACR

Consensus forecasts updated

Consensus forecasts updated

Kazia Therapeutics Limited Announces Phase II Clinical Study at Weill Cornell Medical Center Investigating Paxalisib in Combination with Metformin and a Ketogenic Diet Enrolls First Patient

Kazia Therapeutics Limited Announces First Patient Enrolls in Phase II Clinical Study Investigating Paxalisib in Combination with Metformin and a Ketogenic Diet

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

Price target decreased to AU$1.90

Independent Non-Executive Director recently bought AU$54k worth of stock

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0395 (Paxalisib) Issued by Thenational Medical Products Administration Under Collaboration with Kazia Therapeutics Limited

Kazia Releases Final Data from P2 Paxalisib Trial

No longer forecast to breakeven

We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned

We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth

Full year 2021 earnings released: AU$0.072 loss per share (vs AU$0.17 loss in FY 2020)

Kazia Therapeutics Limited Provides Progress Update on Paxalisib and Evt801 Clinical Programs

Kazia Therapeutics Limited Announces Manufacturing Patents Granted for Paxalisib in Key Territories

Kazia Therapeutics Limited Launches New Paxalisib Phase II Clinical Trial

Kazia Therapeutics Limited Announces Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

Consensus forecasts updated

We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth

Consensus forecasts updated